Institution
Suffolk University
Education•Boston, Massachusetts, United States•
About: Suffolk University is a education organization based out in Boston, Massachusetts, United States. It is known for research contribution in the topics: Population & Sugar beet. The organization has 6462 authors who have published 9321 publications receiving 235328 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years.
Abstract: Background Recurrent vulvovaginal candidiasis (RVVC) is a problematic form of mucosal Candida infection, characterized by repeated episodes per year. Candida albicans is the most common cause of RVVC. Currently, there are no immunotherapeutic treatments for RVVC. Methods This exploratory randomized, double-blind, placebo-controlled trial evaluated an immunotherapeutic vaccine (NDV-3A) containing a recombinant C. albicans adhesin/invasin protein for prevention of RVVC. Results The study in 188 women with RVVC (n = 178 evaluable) showed that 1 intramuscular dose of NDV-3A was safe and generated rapid and robust B- and T-cell immune responses. Post hoc exploratory analyses revealed a statistically significant increase in the percentage of symptom-free patients at 12 months after vaccination (42% vaccinated vs 22% placebo; P = .03) and a doubling in median time to first symptomatic episode (210 days vaccinated vs 105 days placebo) for the subset of patients aged <40 years (n = 137). The analysis of evaluable patients, which combined patients aged <40 years (77%) and ≥40 years (23%), trended toward a positive impact of NDV-3A versus placebo (P = .099). Conclusions In this unprecedented study of the effectiveness of a fungal vaccine in humans, NDV-3A administered to women with RVVC was safe and highly immunogenic and reduced the frequency of symptomatic episodes of vulvovaginal candidiasis for up to 12 months in women aged <40 years. These results support further development of NDV-3A vaccine and provide guidance for meaningful clinical endpoints for immunotherapeutic management of RVVC. Clinical Trials Registration NCT01926028.
107 citations
••
107 citations
••
TL;DR: A framework for the monitoring and evaluation of spatially managed areas (SMAs), which is currently being tested by nine European case studies, provides guidance on the selection, mapping, and assessment of ecosystem components and human pressures, the evaluation of management effectiveness and potential adaptations to management.
107 citations
••
TL;DR: Findings indicate that DBT treatments appear effective in addressing ED behaviors and other forms of psychopathology in ED samples and the expectation that improvements in emotion regulation capabilities drive reductions in ED pathology was not fully supported.
Abstract: Dialectical behavior therapy (DBT) has been proposed as an effective treatment for eating disorders (EDs). We conducted a systematic literature review to locate refereed journal articles testing DBT for the treatment of EDs. We identified 13 studies empirically evaluating treatment efficacy across various settings. Findings, based on mostly uncontrolled trials, indicate that DBT treatments appear effective in addressing ED behaviors and other forms of psychopathology in ED samples. The expectation that improvements in emotion regulation capabilities drive reductions in ED pathology was not fully supported. Further research is necessary to confirm the efficacy of modified DBT treatments for EDs.
106 citations
••
University of Nottingham1, University of Bristol2, Suffolk University3, Ninewells Hospital4, Medway School of Pharmacy5, University of Edinburgh6, National Institutes of Health7, Monash University8, University of Cambridge9, University of Innsbruck10, University of Iowa11, University of Georgia12, National University of Singapore13, University of Pittsburgh14, University of Texas Southwestern Medical Center15, Emory University16, University of Michigan17, Scripps Research Institute18, Purdue University19, Michigan State University20, La Trobe University21, University of Maryland, College Park22
TL;DR: The Concise Guide to PHARMACOLOGY 2021/22 as discussed by the authors provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands.
Abstract: The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15537. In addition to this overview, in which are identified 'Other protein targets' which fall outside of the subsequent categorisation, there are six areas of focus: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
106 citations
Authors
Showing all 6484 results
Name | H-index | Papers | Citations |
---|---|---|---|
Peter Hall | 132 | 1640 | 85019 |
Michael R. Hamblin | 117 | 899 | 59533 |
Miao Liu | 111 | 993 | 59811 |
Rosalind W. Picard | 100 | 461 | 44750 |
Simon Jennings | 94 | 240 | 29030 |
John A. Clark | 94 | 440 | 62221 |
Christopher Hawkes | 93 | 423 | 41658 |
Melanie J. Davies | 89 | 814 | 36939 |
Andrew Smith | 87 | 1025 | 34127 |
Andrew Jones | 83 | 695 | 28290 |
Catherine E. Costello | 82 | 411 | 24811 |
Paul O'Brien | 79 | 808 | 28228 |
Rhys E. Green | 78 | 285 | 30428 |
Nicholas K. Dulvy | 72 | 193 | 22962 |
David L.H. Bennett | 69 | 322 | 17388 |